| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14728214.11.2.231 |
| P698 | PubMed publication ID | 16634699 |
| P50 | author | John R Perfect | Q64932411 |
| P2093 | author name string | Richard H Drew | |
| Michelle S Turner | |||
| P2860 | cites work | In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole | Q24538858 |
| Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia | Q24563657 | ||
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial | Q28278518 | ||
| In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi | Q28343817 | ||
| Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial | Q28359772 | ||
| Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis | Q28377349 | ||
| Echinocandin antifungal drugs | Q29398696 | ||
| Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study | Q29616607 | ||
| Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. | Q30452376 | ||
| Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins | Q31058690 | ||
| In vitro activity of caspofungin against Candida albicans biofilms. | Q31114513 | ||
| In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide | Q31440075 | ||
| In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. | Q31758369 | ||
| Mortality and costs of acute renal failure associated with amphotericin B therapy | Q32068576 | ||
| Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis | Q33803108 | ||
| Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group | Q33854646 | ||
| Epidemiology ofAspergillusInfections in a Large Cohort of Patients Undergoing Bone Marrow Transplantation | Q59512032 | ||
| Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections | Q61758371 | ||
| Susceptibility of clinical isolates of Fusarium to antifungal drugs | Q71485021 | ||
| A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute | Q72741418 | ||
| Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp | Q73172089 | ||
| Posaconazole | Q80403726 | ||
| Amphotericin B: time for a new "gold standard". | Q44527998 | ||
| Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). | Q44565645 | ||
| Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin | Q44583938 | ||
| Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model | Q44636233 | ||
| Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy | Q44683857 | ||
| Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole | Q44703323 | ||
| A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans | Q44733004 | ||
| Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study | Q44832013 | ||
| Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections | Q44879938 | ||
| Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal | Q44897892 | ||
| Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study | Q44952619 | ||
| Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity | Q45066131 | ||
| A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis | Q45096984 | ||
| Combination antifungal therapy for invasive aspergillosis | Q45096994 | ||
| A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients | Q45097002 | ||
| Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy | Q45172488 | ||
| Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine | Q45221761 | ||
| Studies of the paradoxical effect of caspofungin at high drug concentrations | Q46377599 | ||
| Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. | Q46559888 | ||
| In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi | Q46595795 | ||
| Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis | Q46620841 | ||
| Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program | Q46663951 | ||
| Efficacy of micafungin for the treatment of candidemia | Q46772887 | ||
| International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. | Q46784358 | ||
| Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. | Q46820586 | ||
| Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation | Q46859781 | ||
| Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. | Q50700185 | ||
| Invasive mold infections in allogeneic bone marrow transplant recipients. | Q51192154 | ||
| Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. | Q51700168 | ||
| National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. | Q54137486 | ||
| Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome | Q33935389 | ||
| Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates | Q33938068 | ||
| Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients | Q33938201 | ||
| A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan | Q33980368 | ||
| Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent | Q33980499 | ||
| Newer systemic antifungal agents : pharmacokinetics, safety and efficacy | Q33981062 | ||
| Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy | Q33981794 | ||
| Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling | Q33983159 | ||
| Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits | Q33983506 | ||
| Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. | Q34085884 | ||
| Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases | Q34105475 | ||
| Amphotericin B-induced nephrotoxicity: a review | Q34128655 | ||
| Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin | Q34142491 | ||
| In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies | Q34253266 | ||
| Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics | Q34291656 | ||
| Posaconazole as salvage therapy for zygomycosis | Q34301611 | ||
| Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation | Q34368144 | ||
| Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience | Q34455699 | ||
| Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients | Q34553509 | ||
| Safety and tolerability of caspofungin acetate in the treatment of fungal infections | Q34746958 | ||
| Efficacy of micafungin alone or in combination against systemic murine aspergillosis | Q34884594 | ||
| Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis | Q35102603 | ||
| Clinical pharmacology of antifungal compounds | Q35129039 | ||
| A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. | Q35179541 | ||
| Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. | Q35641405 | ||
| Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity | Q35641441 | ||
| Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy | Q35688450 | ||
| Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. | Q35718542 | ||
| In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection | Q35870651 | ||
| Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. | Q35966128 | ||
| Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin | Q36235197 | ||
| Caspofungin: a review of its use in the treatment of fungal infections | Q36257157 | ||
| Advances and challenges in management of invasive mycoses | Q36259905 | ||
| Laboratory diagnosis of invasive aspergillosis. | Q36267587 | ||
| Activity of posaconazole in treatment of experimental disseminated zygomycosis. | Q36880761 | ||
| Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis | Q37118666 | ||
| Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species | Q37157546 | ||
| The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. | Q38356350 | ||
| In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. | Q39651019 | ||
| In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model | Q39652289 | ||
| Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis | Q39652561 | ||
| The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro | Q39652699 | ||
| In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. | Q39652771 | ||
| Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. | Q39652915 | ||
| In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. | Q39657947 | ||
| In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. | Q39731811 | ||
| In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points | Q39743420 | ||
| Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei | Q39743425 | ||
| In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms | Q39743508 | ||
| Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations | Q39954432 | ||
| Caspofungin activity against clinical isolates of fluconazole-resistant Candida | Q40404311 | ||
| Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia | Q40524745 | ||
| Eradication of Invasive Mucormycosis--Effectiveness of the Echinocandin FK463 | Q40559190 | ||
| Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma | Q40622190 | ||
| Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). | Q40644002 | ||
| A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients | Q40645972 | ||
| Oral azole drugs as systemic antifungal therapy | Q40796244 | ||
| In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata | Q41834480 | ||
| Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients | Q42163324 | ||
| Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. | Q42286250 | ||
| Caspofungin in combination with amphotericin B against Candida glabrata | Q42839661 | ||
| Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia | Q43628333 | ||
| A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis | Q43757967 | ||
| Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection | Q43836975 | ||
| Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis | Q43864353 | ||
| Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans | Q43933917 | ||
| In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds | Q43994181 | ||
| Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods | Q44019731 | ||
| Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity | Q44123167 | ||
| A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis | Q44166464 | ||
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin | Q44304226 | ||
| In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp. | Q44340936 | ||
| Attributable mortality of nosocomial candidemia, revisited | Q44386169 | ||
| Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study | Q44396642 | ||
| Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole | Q44403610 | ||
| Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus | Q44418762 | ||
| A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. | Q44440960 | ||
| Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies | Q44519647 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Aminocandin | Q4746450 |
| invasive fungal infections | Q55022218 | ||
| P304 | page(s) | 231-250 | |
| P577 | publication date | 2006-05-01 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Emerging echinocandins for treatment of invasive fungal infections | |
| P478 | volume | 11 |
| Q36723788 | Anidulafungin: a new echinocandin for candidal infections |
| Q37345790 | Anidulafungin: a novel echinocandin for candida infections |
| Q37798956 | Antifungal Treatment of Small Animal Veterinary Patients |
| Q36967212 | Antifungal agents in neonates: issues and recommendations. |
| Q37623837 | Antifungal agents, WO2009025733. |
| Q37775500 | Conazoles. |
| Q40900363 | Differential effects of antifungal agents on expression of genes related to formation of Candida albicans biofilms |
| Q38254290 | Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management |
| Q37557700 | Human fungal pathogen Candida albicans in the postgenomic era: an overview. |
| Q38550402 | Mechanisms of echinocandin antifungal drug resistance |
| Q34006585 | Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis |
| Q43071889 | Msb2 signaling mucin controls activation of Cek1 mitogen-activated protein kinase in Candida albicans |
| Q40049865 | Opportunistic Invasive Cutaneous Fungal Infections Associated with Administration of Cyclosporine to Dogs with Immune-mediated Disease. |
| Q37122826 | Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance |
| Q43105019 | Synthesis and in vitro and in vivo antifungal activity of the hydroxy metabolites of saperconazole |
| Q37075845 | The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. |
Search more.